全文获取类型
收费全文 | 586篇 |
免费 | 39篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 34篇 |
妇产科学 | 3篇 |
基础医学 | 56篇 |
口腔科学 | 7篇 |
临床医学 | 68篇 |
内科学 | 92篇 |
皮肤病学 | 1篇 |
神经病学 | 78篇 |
特种医学 | 172篇 |
外科学 | 52篇 |
综合类 | 12篇 |
预防医学 | 19篇 |
眼科学 | 4篇 |
药学 | 33篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 3篇 |
2021年 | 5篇 |
2020年 | 4篇 |
2019年 | 2篇 |
2018年 | 6篇 |
2017年 | 5篇 |
2016年 | 14篇 |
2015年 | 9篇 |
2014年 | 14篇 |
2013年 | 16篇 |
2012年 | 8篇 |
2011年 | 20篇 |
2010年 | 14篇 |
2009年 | 11篇 |
2008年 | 12篇 |
2007年 | 21篇 |
2006年 | 11篇 |
2005年 | 19篇 |
2004年 | 7篇 |
2003年 | 4篇 |
2002年 | 5篇 |
2001年 | 11篇 |
2000年 | 6篇 |
1999年 | 10篇 |
1998年 | 30篇 |
1997年 | 29篇 |
1996年 | 39篇 |
1995年 | 24篇 |
1994年 | 18篇 |
1993年 | 27篇 |
1992年 | 14篇 |
1991年 | 8篇 |
1990年 | 16篇 |
1989年 | 25篇 |
1988年 | 26篇 |
1987年 | 25篇 |
1986年 | 13篇 |
1985年 | 17篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 20篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1979年 | 4篇 |
1978年 | 2篇 |
1977年 | 9篇 |
1976年 | 18篇 |
1975年 | 7篇 |
排序方式: 共有647条查询结果,搜索用时 0 毫秒
61.
Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation 总被引:2,自引:0,他引:2
Phillips GL; Wolff SN; Herzig RH; Lazarus HM; Fay JW; Lin HS; Shina DC; Glasgow GP; Griffith RC; Lamb CW 《Blood》1989,73(8):2086-2092
Twenty-six patients with progressive Hodgkin's disease after conventional chemotherapy received intensive chemoradiotherapy and autologous bone marrow transplantation (ABMT); 19 also received additional involved-field radiotherapy. Twenty-one patients [81%, 95% confidence intervals (CI) 61% to 94%] attained complete (n = 18) or partial responses. Ten patients (38%, 95% CI 20% to 59%) are disease- free a median of 4.5 years later (range 3.5 to 7.0 years), including seven patients with continuous complete responses. The likelihood of overall response was not significantly influenced by any clinical or treatment variable examined. However, there was a trend favoring patients with higher Karnofsky scores, and higher scores were associated with attainment of complete responses (P = .06 and P = .02, respectively, Mann-Whitney U test). Both higher Karnofsky scores and shorter durations of disease before transplantation were associated with improved survival in a stepwise Cox multivariate analysis. The chief cause of failure was progression at sites previously involved with Hodgkin's disease. No patient relapsed in the marrow, and two of three patients with a history of marrow involvement with Hodgkin's disease achieved durable complete responses after transplantation. These data suggest that inadequate pretransplant conditioning, and not the reinoculation of occult tumor cells in the autologous marrow, caused most relapses. Fatal treatment-related toxicity occurred in six patients. Three patients died of idiopathic interstitial pneumonitis; each had previously received local mediastinal irradiation before intensive chemoradiotherapy. Intensive chemoradiotherapy and ABMT produces durable responses in some patients with Hodgkin's disease incurable with conventional therapy. Use of such therapies at the first sign of failure with conventional chemotherapy and development of more effective conditioning regimens should further improve results. 相似文献
62.
Chung Yu Chan Hong Zhao Raymond J. Pugh Anthony M. Pedley Jarrod French Sara A. Jones Xiaowei Zhuang Hyder Jinnah Tony Jun Huang Stephen J. Benkovic 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(5):1368-1373
The de novo purine biosynthetic pathway relies on six enzymes to catalyze the conversion of phosphoribosylpyrophosphate to inosine 5′-monophosphate. Under purine-depleted conditions, these enzymes form a multienzyme complex known as the purinosome. Previous studies have revealed the spatial organization and importance of the purinosome within mammalian cancer cells. In this study, time-lapse fluorescence microscopy was used to investigate the cell cycle dependency on purinosome formation in two cell models. Results in HeLa cells under purine-depleted conditions demonstrated a significantly higher number of cells with purinosomes in the G1 phase, which was further confirmed by cell synchronization. HGPRT-deficient fibroblast cells also exhibited the greatest purinosome formation in the G1 phase; however, elevated levels of purinosomes were also observed in the S and G2/M phases. The observed variation in cell cycle-dependent purinosome formation between the two cell models tested can be attributed to differences in purine biosynthetic mechanisms. Our results demonstrate that purinosome formation is closely related to the cell cycle.Enzymes have been shown to form clusters in a cell to regulate metabolic processes (1–3). More recently, the concept of multienzyme complexes has been expanded to include mesoscale protein assemblies that appear to be substantially larger than a single protein (4). Depending on the metabolic or developmental state of the cells, these types of protein clusters range from transiently associated to very rigid and well defined (4). Examples of such enzyme clusters include the EF-Tu cytoskeleton, RNA degradosome, CTP synthase, carboxysomes, and nucleolus (5–9).In humans, purine nucleotides are synthesized by two different mechanisms. The first mechanism, de novo purine biosynthesis, converts phosphoribosylpyrophosphate (PRPP) to inosine 5′-phosphate (IMP) in 10 highly conserved steps catalyzed by six enzymes. These six enzymes include one trifunctional enzyme (TrifGART: GARS, GART, and AIRS domains), two bifunctional enzymes (PAICS: CAIRS and SAICARS domains; ATIC: AICART and IMPCH domains), and three monofunctional enzymes (PPAT, FGAMS, and ASL). ASL is also necessary for the conversion of IMP to AMP and may be classified as bifunctional (10). The second mechanism uses nucleotide salvage pathways to either phosphorylate a nucleoside (e.g., thymidine kinase) or add a purine base to ribose 5′-phosphate to regenerate the respective monophosphate. For example, hypoxanthine/guanine phosphoribosyl transferase (HGPRT) catalyzes the conversion of hypoxanthine to IMP and the conversion of guanine to guanosine 5′-phosphate (GMP). The de novo pathway is more energy-intensive, with the synthesis of 1 mole of IMP requiring 5 moles of ATP. Therefore, the salvage pathway is the preferred pathway for purine biosynthesis. Cells deficient in HGPRT, such as those that exhibit a Lesch–Nyhan disease (LND) phenotype, rely primarily on the de novo purine biosynthetic pathway to generate purine nucleotides (11–15).Recently, enzymes in the de novo purine biosynthetic pathway were shown to organize and reversibly assemble into punctate cellular bodies known as “purinosomes” under purine-depleted conditions (16). Further investigations into the organization of the purinosome showed that several of the enzymes form a core structure (PPAT, TrifGART, and FGAMS), whereas others appear to interact peripherally (PAICS, ASL, and ATIC) (17). The presence of this protein assembly and its putative function(s) clearly suggest that the spatial organization of pathway enzymes into purinosomes within a cell play an important role in meeting the cellular demand for purines (18). Although many studies have implied up-regulation of the de novo purine biosynthetic pathway during cell cycle progression (14, 19–21), here we used time-lapse microscopy to determine whether a correlation exists between the cell cycle stage and the number of cells with purinosomes or the cells’ purinosome content. Two different cell types, HeLa and LND cells, were used, with the latter deficient in purine salvage, to assess the effect of increased demand on the de novo pathway for purine biosynthesis and the attendant consequences for purinosome assembly. 相似文献
63.
Wolff SN; Marion J; Stein RS; Flexner JM; Lazarus HM; Spitzer TR; Phillips GL; Herzig RH; Herzig GP 《Blood》1985,65(6):1407-1411
High-dose (HD) cytosine arabinoside (ARA-C) is more effective treatment than conventional-dose ARA-C regimens for patients with relapsed acute nonlymphocytic leukemia (ANLL). We report here that HD ARA-C given during the first remission of ANLL has resulted in long remission durations and a high proportion of patients who survive more than three years free of disease. From August 1979 to September 1983, 36 adult patients with ANLL in first remission received one to three courses of HD ARA-C (3 g/m2 by one-hour infusion every 12 hours for 12 doses on days 1 through 6) alone or with daunorubicin (30 mg/m2 for two or three doses on days 7 through 9). Three patients died of sepsis or hemorrhage during consolidation, and 14 patients have relapsed from five to 48 months after diagnosis. The remaining 19 patients are in continued complete remission (CCR) from 11 to 62 months. Denoting all deaths in remission as relapse, the actuarial probability of CCR is 42% at 62 months, with an apparent plateau in the survival curve. Of the first 22 patients treated, ten remain in CCR from 37 to 62 months with no therapy for at least three years. Due to its heightened anti-leukemic activity, HD ARA-C allows brief but effective consolidation of ANLL in first remission, with long-term disease-free survival comparable to other approaches. 相似文献
64.
世界胃肠病学组织(WGO-OMGE)临床指南——发展中国家幽门螺杆菌感染 总被引:16,自引:1,他引:16
Hunt RH Xiao SD Megraud F Leon-Barua R Bazzoli F Van der Merwe S vaz Coelho LG Fock KM Fedail S Cohen H Malfertheiner P Vakil N Hamid S Goh KL Wong BC Krabshuis JH 杜颖 丛衍群 戴宁 《胃肠病学》2007,12(1):40-52
我非常高兴向大家推荐这份发展中国家幽门螺杆菌(H.priori)临床指南。该指南的编译是由数位在该领域具有丰富临床经验的世界知名专家共同完成的。 相似文献
65.
Baka is a platelet alloantigen whose putative allele, Bakb, has not been identified previously. By using a serum, "Har," obtained from a patient with posttransfusion purpura, we describe the platelet alloantigen Bakb. The Har serum reacted with an NP-40-extractable platelet membrane protein of 142 kd with mobility similar to platelet glycoprotein IIb alpha. We found that the antigen recognized by the Har serum is inherited in an autosomal dominant mode with an apparent gene frequency of .39. Chi-square analysis of observed and expected phenotype frequencies indicated that serum Har recognizes Bakb, the anticipated allele of Baka. Our findings provide new evidence for polymorphism of glycoprotein IIb and for the association of posttransfusion purpura with alloimmunization to determinants on this glycoprotein. 相似文献
66.
Lethal midline granuloma (LMG) is associated with Epstein-Barr virus (EBV). The latter has at least two subtypes with different biological properties. The subtypes can be identified by their genomic configuration. Using EBV-RNA (EBER) in situ hybridization and EBV polymerase chain reaction (PCR), we have looked for the presence of EBV in six LMGs and six non-Hodgkin's lymphomas (NHLs) located in the nasopharyngeal region, and determined the subtype of EBV. Six of six LMGs were positive by PCR and EBER in situ hybridization, whereas NHLs were either negative or, in three of six cases, showed few EBER- positive cells considered to be nonneoplastic lymphocytes. The subtype 2 was found in LMG lesions of three of six patients; the remaining three of six patients with LMG had the generally occurring subtype 1. The results indicate that the association of EBV with NHL may depend more on tumor type than on its localization. The occurrence of the rare subtype 2 in LMG may relate to a covert immune defect. 相似文献
67.
The clinical history and histological features of seven cases of granulomatous mastitis are presented. The lesion occurs in young parous women as a tender extra-areolar breast lump. Histologically, non-caseating discrete granulomas are present, confined to breast lobules with, in three cases, coalescence of the granulomas and microabscess formation. Pathogenesis of the changes is discussed. It is thought that granulomatous mastitis is an entity morphologically distinct from duct ectasia/plasma cell mastitis and the commoner forms of granulomatous breast diseases. 相似文献
68.
69.
70.
Erythropoietin structure-function relationships: high degree of sequence homology among mammals 总被引:7,自引:3,他引:4
Wen D; Boissel JP; Tracy TE; Gruninger RH; Mulcahy LS; Czelusniak J; Goodman M; Bunn HF 《Blood》1993,82(5):1507-1516
To investigate structure-function relationships of erythropoietin (Epo), we have obtained cDNA sequences that encode the mature Epo protein of a variety of mammals. A first set of primers, corresponding to conserved nucleotide sequences between mouse and human DNAs, allowed us to amplify by polymerase chain reaction (PCR) intron 1/exon 2 fragments from genomic DNA of the hamster, cat, lion, dog, horse, sheep, dolphin, and pig. Sequencing of these fragments permitted the design of a second generation of species-specific primers. RNA was prepared from anemic kidneys and reverse-transcribed. Using our battery of species-specific 5' primers, we were able to successfully PCR- amplify Epo cDNA from Rhesus monkey, rat, sheep, dog, cat, and pig. Deduced amino acid sequences of mature Epo proteins from these animals, in combination with known sequences for human, Cynomolgus monkey, and mouse, showed a high degree of homology, which explains the biologic and immunological cross-reactivity that has been observed in a number of species. Human Epo is 91% identical to monkey Epo, 85% to cat and dog Epo, and 80% to 82% to pig, sheep, mouse, and rat Epos. There was full conservation of (1) the disulfide bridge linking the NH2 and COOH termini; (2) N-glycosylation sites; and (3) predicted amphipathic alpha- helices. In contrast, the short disulfide bridge (C29/C33 in humans) is not invariant. Cys33 was replaced by a Pro in rodents. Most of the amino acid replacements were conservative. The C-terminal part of the loop between the C and D helices showed the most variation, with several amino acid substitutions, deletions, and/or insertions. Calculations of maximum parsimony for intron 1/exon 2 sequences as well as coding sequences enabled the construction of cladograms that are in good agreement with known phylogenetic relationships. 相似文献